Common Variable Immunodeficiency
2
Pipeline Programs
1
Companies
3
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
1
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
1 companies ranked by most advanced pipeline stage
CSL BehringIL - Bradley
3 programs1
1
VivaglobinPhase 41 trial
Human Normal Immunoglobulin for Subcutaneous AdministrationPhase 31 trial
gammaglobulinN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
CSL BehringVivaglobin
CSL BehringHuman Normal Immunoglobulin for Subcutaneous Administration
CSL Behringgammaglobulin
Clinical Trials (3)
Total enrollment: 74 patients across 3 trials
Efficacy and Safety of Vivaglobin® in Previously Untreated Patients With Primary Immunodeficiency
Start: Mar 2007Est. completion: Oct 200818 patients
Phase 4Completed
Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy
Start: Sep 2007Est. completion: Aug 200951 patients
Phase 3Completed
Specific IgG Antibody in Patients With Primary Antibody Deficiencies Treated With Subcutaneous Immunoglobulin
Start: Jan 2002Est. completion: Nov 20025 patients
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 late-stage (Phase 3) programs — potential near-term approvals
1 companies competing in this space